Search
  Share Print Page
 

LIFE SCIENCES

We help clients keep up and thrive in a constantly shifting landscape. Our attorneys are at the forefront of industry trends, advising clients on everything from adopting new business models and navigating the regulatory landscape, to devising innovative IP protection and monetization strategies.

Our approach

The global life sciences industry is advancing rapidly. Increased generic competition, the changing patent landscape, evolving regulations, and pricing pressures present new challenges and opportunities for companies across the sector.

Our cross-disciplinary team can steer you through every phase of your life cycle, helping you carefully consider all of your options, and execute effective growth strategies—whether through licensing, M&A deals, or other types of transactions.

And while we have a lot of experience with transactions and litigation for large public companies, we have a passion for helping mid-market and start-up companies grow.

The rapidly changing life sciences ecosystem presents a lot of exciting opportunities. We’re focused on helping clients leverage those opportunities and make strategic decisions that maximize their business potential.

Who we work with

  • Biotech companies
  • Medical device companies
  • Pharmaceutical companies
  • Academic medical centers
  • Leading universities

Representative Corporate, Regulatory, and Transactional Matters:

  • Representing a Canadian company in coordinating the research, development and licensing of medical isotope technology with a U.S. Government laboratory and state university.
  • Representing a start-up company developing a care model for diabetes in the licensing of intellectual property from a university and the formation of a joint venture with a bioinformatics company to develop and commercialize the technology.
  • Represented the world's largest biological resource center and the most comprehensive source of reference cultures and reagents used by researchers, in negotiating and drafting numerous distribution and development agreements with companies throughout the world.
  • Counseling a large biologics company, providing an opinion on the eligibility of its new drug product for marketing exclusivity and patent term extension.
  • Representing a medical device company in responding to an FDA import detention and refusal involving products made by its contract manufacturer in China, and responding to a Form FDA-483, Inspectional Observations, regarding compliance with Current Good Manufacturing Practice (“CGMP”) requirements.
  • Assisting a large biologics manufacturer on the preparation of a challenge to an FDA decision awarding orphan drug exclusivity to a competitor.
  • Represented a biologics company in preparing and obtaining a successful response to a citizen’s petition from the FDA. The problem involved limits on orphan drug designation.
  • Advised a biopharmaceutical company focused on new drugs candidates targeting GPCR, in a multi-million dollar financing.
  • Advised a company specializing in proton therapy treatment, in its $10 million financing from existing shareholders.
  • Advised a French biopharmaceutical company in its fund raising from seed to Series A, B and C rounds, and on a broad range of matters such as build-up operations, mergers, spin-off, asset deals, employment and executive management remuneration and incentive packages, joint venture agreements, and partnerships.
  • Represented a biotechnology company focused on novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes, in negotiating a license into the company relating to its core technology, and represent the company with regard to the creation and maintenance of its stock option plan and other general legal matters.
  • Represented a growth-stage medical device company focused on the development of biodegradable silk-based scaffolds for use in tissue regeneration in numerous therapeutic areas in its sale to a multi-specialty health care company that develops pharmaceuticals, biologics, medical devices and over-the-counter consumer products.
  • Represented a Swedish medicinal and analytical chemistry company in the acquisition of two product lines and associated business from a leading provider of cutting-edge technologies in the life science industry.
  • Represent a well-known biopharmaceutical company in a variety of real estate transactions including leasing, permitting, construction contracting, and financing, related to multiple client facilities and offices.
  • Handle leasing work on behalf of a large manufacturer of analytical and medical instruments.

Representative Litigation Matters:

  • Represented the plaintiff, a well-known medical device company, in a patent infringement case in the U.S. District Court for the District of Massachusetts. Our client was awarded a multi- million dollar verdict for lost profits and a 16% royalty (on sales not included in lost profits).
  • Represented one of the largest healthcare companies in the world in connection with the company’s global settlement of three separate government investigations for $3 billion—the largest health care fraud settlement in U.S. history. Of the three investigations, Nixon Peabody attorneys were the primary counsel for the company in the defense of an investigation by the Department of Justice relating to the company’s Medicaid “best price” reporting. Our attorneys were also significantly involved in the defense of the investigation by the U.S. Attorney’s Office for the District of Massachusetts relating to the government’s allegations of off-label promotion and anti-kickback violations. The case settled favorably for our client.
  • Represented the plaintiff, a leading medical device company, in a patent infringement case in the U.S. District Court for the Northern District of Illinois. The case was settled on terms favorable to our client.
  • Served as Counsel for over 66 pharmaceutical companies in role as liaison counsel for Average Wholesale Pricing matters venued in commercial court in New York. The case was favorably resolved for our clients.
  • Currently defending Shire Human Genetic Therapies in a Lanham Act false advertising case brought by Genzyme.
  • Represented a pharmacy chain and a national grocery store and in a putative class action in the Northern District of California involving alleged inflation of average wholesale pricing (AWP) for prescription drugs by national pharmacy chains Supervalu Inc., New Albertson’s Inc., Walgreens Co., Longs Drugs Stores Corp., The Kroger Co., Safeway Inc., Wal-Mart Stores Inc., CVS Caremark Corp., and Rite Aid Corp. In January 2010, the case was dismissed with prejudice by the trial court for failure to state a claim. On February 9, 2012, the Ninth Circuit Court of Appeals unanimously affirmed the trial court’s dismissal.

Awards & Rankings

  • The Legal 500 United States
    • Recommended as a leader in the Healthcare: Life Sciences industry
  • Managing IP magazine’s World IP Survey
    • Recognized as a national leader in the patent category for bio life sciences

Media Clips

  • The Past, Present and Future of Stem Cells
    Daily Journal | August 27, 2014
    Los Angeles office managing partner Seth Levy and Los Angeles patent agent Stephen Chen co-authored this column looking at the state of stem cells and what’s next.
  • Dealmakers Q&A
    Law360 | August 13, 2014
    Health Care and Life Sciences leader Michele Masucci is profiled in this Law360 Q&A series with dealmaking movers and shakers.
  • FDA's Biggest New Policies of 2014: Midyear Report
    Law360 | July 28, 2014
    Washington, DC, Health Care and Life Sciences partner Areta Kupchyk is quoted in this forward-looking feature story on new rules and guidance from the U.S. Food and Drug Administration making waves for drug and device makers.
  • . . . View all . . .
  • What's Trending with Mobile Medical Apps and Health IT?
    Bloomberg BNA Health IT Law & Industry Report | July 21, 2014
    Washington, DC, Health Care and Life Sciences partner Areta Kupchyk authored this article discussing a potential new Food and Drug Administration framework for mobile medical apps and health IT. Click here to read the full article.
  • 5th Circ. Continues Trend Against 'Innovator Liability'
    Law360 | June 16, 2014
    Boston Commercial Litigation partner Chris Allen and Boston Commercial Litigation associate Josh Barlow authored this column discussing the decision in Eckhardt v. Qualitest Pharmaceuticals Inc., which rejected theories of “innovator liability” asserted against manufacturers of branded drugs.
  • Personalized Medicine Changes the Rules of the Play (Personoitu Laaketiede Muuttaa Pelisaantoja)
    Mediuutiset (Finland) | March 21, 2014
    In this Finnish health care publication, Boston Patents counsel Leena Karttunen Contarino provides commentary on how the FDA defines personalized medicine and about the FDA’s attempts to handle personalized medicine drugs and devices in an integrated process.
  • 5 Lessons Doctors Can Take From FDA's Big Stem-Cell Win
    Law360 | February 7, 2014
    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk discusses the DC Circuit Court’s stem cell oversight decision.
  • Sisters of Charity of Leavenworth Health System and St. James Healthcare Agree to Pay $3.85 Million to Resolve Fraud and Abuse Allegations
    American Health Lawyers Association | January 6, 2014
    Boston Government Investigations & White Collar Defense partner Brian French discusses the implications of the agreement between the U.S. Department of Justice (DOJ) and St. James Healthcare and its parent company, Sisters of Charity of Leavenworth Health System, to pay nearly $4 million to resolve alleged violations of the Anti-Kickback Statute, the Stark Law, and the False Claims Act.
  • Health Care Cases to Watch in 2014
    Law360 | January 1, 2014
    Boston Government Investigations & White Collar Defense partner Brian French discusses the high-profile False Claims Act suit, Nathan v. Takeda, that could provide clarity on the muddled question of how precisely a whistleblower must describe fraud.
  • Life Sciences Cases to Watch in 2014
    Law360 | January 1, 2014
    Boston Commercial Litigation and Life Sciences partner Fred Kelly discusses the U.S. Supreme Court’s consideration of reviewing the Fourth Circuit’s dismissal of a Takeda Pharmaceutical Co. Ltd. salesman’s claims that the company marketed the drug Kapidex off-label and caused improper Medicare billing.
  • Life Sciences Regulation and Legislation to Watch in 2014
    Law360 | January 1, 2014
    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk discusses FDA’s involvement in laboratory-developed testing, momentum on biosimilars, and possible further guidance on developing tailored medications.
  • 2013's Game-Changing Health Rulings
    Law360 | December 17, 2013

    Boston Government Investigations & White Collar Defense partner and a member of the firm’s Life Sciences practice Brian French discusses high-stakes cases for the health industry including those involving False Claims Act litigation and reimbursement disputes.

  • Personalized Medicine Providers, FDA Has Your Back
    Law360 | December 8, 2013
    Boston Patents counsel Leena Karttunen Contarino and Washington, DC, Health Services and Life Sciences partner Areta Kupchyk authored this column discussing the U.S. Food and Drug Administration’s comprehensive personalized medicine report.
  • 4 Little-Noticed FCA Rulings Attys Need To Know
    Law360 | December 2, 2013

    Boston Government Investigations & White Collar Defense partner and member of the Life Sciences practice Brian French discusses recent False Claims Act lawsuits likely to reshape a litigation landscape particularly in health care and life sciences.

  • FDA's Stem Cell Oversight Faces Pivotal Test in DC Circ.
    Law360 | October 22, 2013
    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk discusses the importance of a DC Circuit case focused on the U.S. Food and Drug Administration’s power to regulate stem cell therapy.
  • Maine Law Muddles Liability in Drug Injury Suits
    Law360 | October 11, 2013
    Boston Life Sciences and IP Litigation partner Joe Leghorn provides commentary on a new Maine law, a first of its kind in the U.S., allowing prescription drugs to be purchased from foreign pharmacies.
  • The Intersection of Off-Label Promotion and Free Speech
    ABA Criminal Litigation Newsletter | October 9, 2013
    Boston Government Investigations & White Collar Defense partner Gerry Leone and associates Hannah Bornstein and Conor Harris discuss recent developments in free-speech protection, which reflect a shifting environment for prosecutors investigating pharmaceutical and medical device companies for potential off-label promotional activities.
  • 5 Takeaways from FDA's Unique Device ID Rule
    Law360 | September 27, 2013
    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk comments on the U.S. Food and Drug Administration’s final rule on unique device identification.
  • Myriad Decision Aftershocks Ripple through Biotech
    Nature Biotechnology | August 8, 2013

    Co-leader of the Patents practice and Life Sciences partner David Resnick discusses the impact of the June 2013 U.S. Supreme Court decision in the Myriad Genetics case.

  • Everything You Need to Know About the Sunshine Act
    British Medical Journal | July 26, 2013
    Boston Government Investigations & White Collar Defense partner Brian French, a member of the firm's Life Sciences practice, authored this piece on the Physician Payments Sunshine Act, part of the Affordable Care Act.
  • The Federal Regulation of Mobile Medical Apps
    Update: Food and Drug Law, Regulation and Education | July 1, 2013

    Health Services and Life Sciences partner Areta Kupchyk, Global Business & Transactions partner Mavis Yee, and Health Services and Life Sciences associate Carly Eisenberg authored this article on the need to balance the increasing use of mobile apps in the medical field with the need to protect the public. Click here to read the article online.

  • Patent Troll Lawsuits Rare In Device Industry, But May Increase, Attorneys Say
    The Gray Sheet | June 24, 2013

    Chicago partner and leader of the firm’s Intellectual Property Litigation practice Russ Genet discusses the trend of lawsuits from firms that buy up device patents purely to pursue litigation becoming more commonplace.

  • Plan B Saga Exposes FDA to Drug-Approval Suits
    Law360 | June 19, 2013

    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk discusses the U.S. Food and Drug Administration’s battle against wider access to Plan B emergency contraception.

  • SCOTUS: Human Genes Can't Be Patented
    CNBC | June 13, 2013

    Co-leader of the firm’s Patents practice and member of the Life Sciences team David Resnick discusses the U.S. Supreme Court’s ruling that human genes cannot be patented, striking down Myriad Genetics Inc.'s patents on isolated DNA associated with an increased risk of breast cancer.

  • High Court's Myriad Ruling Won't Crush Biotech Industry
    Life Sciences Law360 | June 13, 2013

    Co-leader of the firm’s Patents practice and member of the Life Sciences team Ron Eisenstein discusses the U.S. Supreme Courts’ ruling that human genes cannot be patented, striking down Myriad Genetics Inc.’s patents on isolated DNA associated with an increased risk of breast cancer.

  • Am Law Firms Look to Land Clients on the Ground Floor
    The American Lawyer | June 1, 2013

    Boston associates Courtney New and Mahmood Firouzbakht discuss their involvement with the Cambridge Innovation Center, the largest flexible office facility for growing technology and life sciences companies in the Greater Boston area.

  • FDA Cracking Down on Compounders at Historic Pace
    Law360 | April 22, 2013

    Washington, DC, health services and life sciences partner Areta Kupchyk provides commentary in this feature article discussing the U.S. Food and Drug Administration’s efforts to police the compounding pharmacy sector.

  • Medical App Makers Await Regulator Checkups
    The Recorder | March 15, 2013

    Silicon Valley Global Business & Transactions partner Mavis Yee and Washington, DC, Health Services and Life Sciences partner Areta Kupchyk are featured throughout this article noting that the mobile medical app industry is awaiting formal regulatory guidelines from lawmakers.

  • Social Media and the De-Identification of Protected Health Information
    Bloomberg BNA Social Media Law & Policy Report | March 12, 2013
    This article, co-authored by partner & leader of the health services practice Michele Masucci and Long Island health services associate Carly Eisenberg, addresses the rising popularity of social media bring new challenges for health care providers. Click here to read the article.
  • FDA's New Safety Reports Raise Tort Risks for Device Cos.
    Law360 | March 8, 2013

    Washington, D.C. health services and life sciences partner Areta Kupchyk discusses the Food and Drug Administration’s draft guidance intended to clarify when a change to a medical device should be considered a “recall” versus a “product enhancement.”

  • Life Sciences Editorial Advisory Board
    Law360 | February 11, 2013

    Boston Commercial Litigation and Life Sciences partner Fred Kelly is highlighted among the Life Sciences Law360 editorial advisory board.

  • Attorney Discusses Concerns about FDA MMA Draft Guidance
    FierceMobileHealthcare | February 4, 2013

    Silicon Valley partner Mavis Yee discusses the U.S. Food and Drug Administration's expected final guidance for mobile medical application developers. Click here to read the article.

  • FDA's Authority to Regulate Pharmacy Compounding: Who's Responsible?
    Corporate Compliance Insights | January 16, 2013

    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk authored this column on the enforcement authority of the Food and Drug Administration (FDA) to regulate the creation of a particular pharmaceutical product to fit the unique needs of a patient. Click here to read the article.

  • Life Sciences Cases to Watch in 2013
    Life Sciences Law 360 | January 1, 2013

    In this article focused on key life sciences industry lawsuits in the coming calendar year, Boston Government Investigations & Life Sciences partner Brian French provides commentary.

  • Life Sciences Regulation to Watch in 2013
    Life Sciences Law 360 | January 1, 2013

    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk and Boston Government Investigations & Life Sciences partner Brian French discuss key life sciences industry regulations to watch in 2013.

  • FDA Marketing Rules Stretch to Drugmakers' Media Pitches
    Law 360 | November 13, 2012

    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk comments on the standard practice of the U.S. Food and Drug Administration to reprimand companies for any marketing efforts that seem to be unfair or misleading regardless if they are directed at consumers or the media.

  • Top 40 Angelenos to Know in Intellectual Property Law
    Los Angeles Business Journal | October 29, 2012

    Los Angeles Patents partner Seth Levy is profiled in this special section highlighting “Who’s Who” in intellectual property in the region.

  • Handling an FDA inspection: Dos, Don'ts and When to Call a Lawyer
    Corporate Compliance Insights | August 20, 2012

    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk authored this column discussing how to handle a facilities investigation by the Food and Drug Administration. Click here to read the article.

  • Washington Roundup: Federal Circuit Broadens Hatch-Waxman Safe Harbor
    BioWorld Today | August 7, 2012

    This article recaps a recent U.S. Court of Appeals decision expanding the safe harbor for generic drug makers. Washington, DC, patents counsel Mary Webster is quoted discussing how expanding the safe harbor will affect patent claims.

  • Drug, Device, and Biotechnology Manufacturing Requirements
    Corporate Compliance Insights | July 2, 2012

    This contributed article, authored by Washington, DC, Health Services and Life Sciences partner Areta Kupchyk, discusses the importance of compliance with current good manufacturing practice regulations established and enforced by the Food and Drug Administration. Click here to read the article.

  • Off-Label Communications: The FDA's Proposed Approach
    Product Liability Law & Strategy | July 1, 2012

    This article, authored by Washington, DC, Health Services and Life Sciences partner Areta Kupchyk and Buffalo Products associate Tracey Ehlers, discusses the Food and Drug Administration guidance addressing how drug, biologics, and medical device manufacturers should respond to unsolicited requests for off-label information, including—for the first time—communications via the Internet and social media.

  • Comment: FDA's Draft Guidance on Social Media and Off-Label Communications
    Bloomberg BNA Social Media Law & Policy Report | June 19, 2012
    Washington, DC, Life Sciences and Health Services partner Areta Kupchyk authored this article discussing the Food & Drug Administration’s long-awaited draft guidance on off-label use communications by drug, biologics, and device companies including, specifically, electronic communications using the Internet and social media.
  • Q&A With Nixon Peabody’s Areta Kupchyk
    Life Sciences Law 360 | May 23, 2012

    This Q&A focused on the life sciences industry is conducted with Washington, DC, Health Services and Life Sciences partner Areta Kupchyk.

  • Business of Law: Nixon Peabody Expands IP Practice in L.A. with Davis Wright Team
    Bloomberg News | May 8, 2012

    This article highlights the arrival of Los Angeles Patents and Life Sciences partner Seth Levy and his team.

  • Q&A With Nixon Peabody’s Fred Kelly
    Life Sciences Law 360 | May 8, 2012

    Boston Commercial Litigation and Life Sciences partner Fred Kelly is featured in this Q&A discussing the life sciences industry.

  • The Park Doctrine and AIP: Two Little-Known But Powerful FDA Enforcement Tools
    Corporate Compliance Insights | April 17, 2012

    Washington, DC, Health Services and Life Sciences partner Areta Kupchyk authored this column addressing two enforcement tools used by the Food and Drug Administration (FDA) in response to violations. Click here to read the article.

  • Strengthening Personalized Medicine Deals
    Genetic Engineering & Biotechnology News | March 1, 2012

    Washington, DC, Global Business & Transactions and Life Sciences partner Mark Kass discusses diagnostic collaboration relationships and how to approach these agreements in this legal affairs column.

  • Stem Cells, FDA, and the Edge of Science: Three Expert Viewpoints
    Forbes | February 19, 2012

    This feature article discusses the challenges with regulating stem cell product development. Washington, DC, Health Services and Life Sciences partner Areta Kupchyk discusses the difficulties involved with regulating cell-based products.

  • FDA’s Draft Guidance on Social Media and Off-Label Communications
    Bloomberg BNA | January 25, 2012
    This contributed article, authored by Washington, DC, Health Services and Life Sciences partner Areta Kupchyk, discusses the draft guidance issued by the FDA about off-label use communications by drug, biologics, and device companies including, specifically, electronic communications using the Internet and social media.
  • Personalized Medicine Could Hinge on Supreme Court Ruling
    BioWorld Today | December 8, 2011

    This story notes that the future of personalized medicine rests in the hands of the U.S. Supreme Court as it mulls arguments in Mayo Collaborative Services v. Prometheus Laboratories Inc. Patents practice co-leader and member of the firm’s Life Sciences practice David Resnick provides third-party commentary.

  • Nixon Peabody Wins Over FDA Insider From Reed Smith
    Law 360 | December 5, 2011

    This feature article highlights the arrival of Washington, DC, Health Services and Life Sciences partner Areta Kupchyk.

  • Reed Smith Attorney in D.C. Jumps to Nixon Peabody
    National Law Journal/Blog of Legal Times | November 28, 2011

    This article highlights the arrival of Washington, DC, Health Services and Life Sciences partner Areta Kupchyk.

Ideas

D.C. Circuit upholds attorney-client privilege in internal compliance investigation
Government Investigations & White Collar Defense Alert | June 30, 2014

The FDA announces long-awaited draft social media guidance for drug and medical device industry
FDA Alert | June 18, 2014

. . . View all . . .

Changes to SEC Rule 701 under the Encouraging Employee Ownership Act: What you need to know
Government Relations Alert | June 16, 2014

Supreme Court allows POM suit against Coca-Cola for Lanham Act violations
Intellectual Property Law Alert | June 12, 2014

Fifth Circuit slams the door shut on innovator liability and rejects attempted end-run around Mensing
Life Sciences Alert | May 23, 2014

Initial take on U.S. Patent Office's public forum on new 101 subject matter eligibility guidelines
Life Sciences Alert | May 12, 2014

The FDA proposes expansion of five-year marketing exclusivity for new chemical entities
Pharmaceutical, Medical Device and Life Sciences Alert | March 6, 2014

Personalized medicine patent watch
Intellectual Property Law Alert | February 27, 2014

Federal court keeps stem cell products under FDA's rule
Pharmaceutical, Medical Device And Life Sciences Alert | February 11, 2014

Clearstream to pay $152 million to U.S. over Iran sanctions claim
Export Controls and Economic Sanctions Alert | January 31, 2014

What You Need to Know About the Personalized Medicine Report by FDA
FDA Law Alert | November 5, 2013

Expansive False Claims Act Theories Gain Traction in Eighth Circuit Ruling
Government Investigations & White Collar Defense Alert | October 22, 2013

FDA asks medical device industry to identify and mitigate cyberattack risks
Pharmaceutical, Medical Device & Life Sciences Alert | June 18, 2013

Personalized Medicine Patent Watch - June 2013
Intellectual Property Alert | June 12, 2013

CMS to hold town hall teleconference for physicians and teaching hospitals regarding the Physician Payment Sunshine Act
Health Alert | May 10, 2013

Hospitals and other providers of medical services and devices may find themselves subject to federal contractor requirements
Health Law Alert | April 25, 2013

Recall or product enhancement? Medical device manufacturers invited to comment on proposed FDA guidance
Pharmaceutucal, Medical Device & Life Sciences Alert | February 26, 2013

Webinar Recording: The New World of Raising Capital in Life Sciences
Originally recorded December 13, 2012 | December 14, 2012

Webinar Recording: The First Amendment and Off-Label Promotion: Understanding the Implications of U.S. v. Caronia
Originally recorded December 5, 2012 | December 6, 2012

Personalized Medicine Patent Watch
Intellectual Property Alert | October 31, 2012

Nixon Peabody's 2012 MAC Survey
October 22, 2012

Webinar Recording: Leveraging Philanthropic Capital to Fund Life Science Companies and University Spin-outs
Originally recorded September 24, 2012 | September 26, 2012

Personalized Medicine Patent Watch Update
Intellectual Property Alert | July 9, 2012

Webinar Recording: Avoiding the Glare of Government Scrutiny: Understanding the implications of the Physician Payment Sunshine Act
Originally recorded June 28, 2012 | July 2, 2012

Supreme Court holds that pharmaceutical reps meet the outside sales exemption to the FLSA
Employment Law Alert | June 18, 2012

HHS releases proposed rule on Stage 2 requirements for meaningful use of EHRs
Health Law Alert | March 9, 2012

FDA issues biosimilar draft guidance
FDA Alert | February 28, 2012

Claims to investment tool too "abstract" to be patent eligible under 35 USC § 101
Intellectual Property Alert | February 28, 2012

FDA's draft guidance on social media and off-label communications
FDA Alert | January 26, 2012

At the Brink of Transformation: What Stephen Berger's report means for health care system board members
Health Law Alert | January 26, 2012

Crafting personalized medicine IP protection—walking the thin line between patent eligibility and enforcement
Intellectual Property Alert | January 10, 2012

FAQs on the final ACO regulations
Health Law Alert | December 28, 2011

First true induced pluripotent stem cell (iPSC) patent issued by the USPTO
Intellectual Property Alert | November 2, 2011

California Court of Appeal affirms award of pre- and post- statutory settlement offer expert witness fees and the reasonableness of a relatively low pretrial settlement offer
Product Liability Alert | November 1, 2011

CMS Releases Final ACO Rule!
Health Law Alert | October 24, 2011

. . . Hide Thought Leadership. . .

Press

Events

Life Sciences